3 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 3 |
| Phase 1 | 1 | Completed 1 |
Follow dinaciclib: new trials by email Literature Review of dinaciclib trials Research Report on dinaciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemia Dinaciclib, Laboratory Biomarker Analysis, Ofatumumab - Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 36 | 2012-01-01 | 2018-03-15 |
| Dinaciclib in Treating Patients With Relapsed or Refractory Multiple Myeloma dinaciclib, laboratory biomarker analysis - Refractory Multiple Myeloma | Phase 2 | Completed | National Cancer Institute (NCI) | 16 | 2009-07-01 | 2014-06-18 |
| SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716) SCH 727965, Capecitabine, Erlotinib - Breast Neoplasms, Carcinoma, Non-Small-Cell Lung | Phase 2 | Completed | Merck Sharp & Dohme LLC | 97 | 2008-07-01 | 2015-08-05 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Leukemia, Prolymphocytic (1) · Multiple Myeloma (1)
National Cancer Institute (NCI) (2) · Merck Sharp & Dohme LLC (1)
United States (2) · Singapore (1)
Kerry Rogers, MD (1) · Shaji Kumar (1)
PMID 24388167, PMID 24393852, PMID 25395429
N01CM00070 (1), N01CM62205 (1), N01CM62207 (1), P30CA015083 (1), P30CA016058 (1), P50CA140158 (1), U01CA076576 (1), UM1CA186712 (1)